Circio Holding ASA (CRNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Circio Holding ASA (CRNA) has a cash flow conversion efficiency ratio of 2.069x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-25.66 Million ≈ $-2.70 Million USD) by net assets (Nkr-12.40 Million ≈ $-1.30 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Circio Holding ASA - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Circio Holding ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Circio Holding ASA (CRNA) total liabilities for a breakdown of total debt and financial obligations.
Circio Holding ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Circio Holding ASA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dongsung Corporation
KO:102260
|
0.050x |
|
Source Energy Services Ltd
TO:SHLE
|
0.166x |
|
Entech SE SAS
PA:ALESE
|
0.142x |
|
Binh Dien Fertilizer JSC
VN:BFC
|
0.217x |
|
SSH Communications Security Oyj
HE:SSH1V
|
-0.076x |
|
Gordon Auto Body Parts Co Ltd
TW:1524
|
0.013x |
|
Gabelli MultiMedia Mutual Fund
NYSE:GGT
|
N/A |
|
Douglas Elliman Inc
NYSE:DOUG
|
-0.078x |
Annual Cash Flow Conversion Efficiency for Circio Holding ASA (2020–2024)
The table below shows the annual cash flow conversion efficiency of Circio Holding ASA from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Circio Holding ASA.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr-12.51 Million ≈ $-1.32 Million |
Nkr-40.53 Million ≈ $-4.27 Million |
3.240x | +257.97% |
| 2023-12-31 | Nkr-98.54 Million ≈ $-10.37 Million |
Nkr-89.20 Million ≈ $-9.39 Million |
0.905x | +102.13% |
| 2022-12-31 | Nkr2.57 Million ≈ $270.02K |
Nkr-108.84 Million ≈ $-11.45 Million |
-42.417x | -20647.19% |
| 2021-12-31 | Nkr417.73 Million ≈ $43.96 Million |
Nkr-85.40 Million ≈ $-8.99 Million |
-0.204x | +31.25% |
| 2020-12-31 | Nkr372.59 Million ≈ $39.21 Million |
Nkr-110.79 Million ≈ $-11.66 Million |
-0.297x | -- |
About Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a … Read more